Stryker (NYSE:SYK) PT Raised to $378.00

Stryker (NYSE:SYK) had its price objective hoisted by equities research analysts at Robert W. Baird from $367.00 to $378.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the medical technology company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 12.39% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. Truist Financial increased their price objective on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research report on Wednesday, January 31st. TD Cowen upped their target price on shares of Stryker from $365.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. BTIG Research increased their price objective on Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research note on Wednesday. Evercore ISI upped their target price on shares of Stryker from $340.00 to $370.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Finally, Roth Mkm increased their price objective on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Four analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $345.48.

Stryker Stock Down 0.8 %

NYSE SYK opened at $336.32 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.58 and a debt-to-equity ratio of 0.59. Stryker has a 52 week low of $249.98 and a 52 week high of $361.41. The business’s fifty day simple moving average is $348.44 and its 200-day simple moving average is $316.70. The firm has a market cap of $127.96 billion, a PE ratio of 40.77, a P/E/G ratio of 2.73 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.14. The company had revenue of $5.24 billion for the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.14 earnings per share. As a group, equities analysts anticipate that Stryker will post 11.86 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at $1,317,414. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares of the company’s stock, valued at $4,856,522. The disclosure for this sale can be found here. In the last three months, insiders sold 212,109 shares of company stock valued at $72,845,768. Company insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Burkett Financial Services LLC acquired a new position in Stryker in the 4th quarter worth $25,000. Farmers & Merchants Trust Co of Chambersburg PA lifted its stake in shares of Stryker by 203.3% in the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Rogco LP purchased a new position in Stryker in the fourth quarter valued at about $30,000. DSM Capital Partners LLC acquired a new stake in Stryker during the 4th quarter valued at approximately $34,000. Finally, HBC Financial Services PLLC purchased a new stake in Stryker during the 4th quarter worth approximately $37,000. 77.09% of the stock is owned by institutional investors and hedge funds.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.